MaxCyteMXCT -2.36%62 PB Ratio is 0.80 as of Jun. 26, 2026, which is 60% below its 10-year median of 2.01. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 788 Medical Devices & Instruments companies, MaxCyte ranks better than 84.9% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), MaxCyte's share price is $1.25. MaxCyte's Book Value per Share for the quarter that ended in Mar. 2026 was $1.57. Hence, MaxCyte's PB Ratio of today is 0.80.
The historical rank and industry rank for MaxCyte's PB Ratio or its related term are showing as below:
MXCT'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 2.01 Max: 18.49
Current: 0.79
During the past 13 years, MaxCyte's highest PB Ratio was 18.49. The lowest was 0.43. And the median was 2.01.
MXCT's PB Ratio is ranked better than 84.9% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs MXCT: 0.79
During the past 12 months, MaxCyte's average Book Value Per Share Growth Rate was -16.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -13.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MaxCyte was 121.50% per year. The lowest was -15.50% per year. And the median was 20.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MaxCyte PB Ratio Related Terms
MaxCyte PB Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's PB Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
MaxCyte's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MaxCyte (MXCT) has a PB Ratio of 0.80 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MaxCyte and its competitors. This is 60% below median its historical median of 2.01. Over the past decade, MaxCyte's PB Ratio has ranged from 0.43 to 18.49. According to the industry distribution chart, MaxCyte ranks #119 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 15.1%.
Is MaxCyte's PB Ratio too high?
MaxCyte's current PB Ratio of 0.80 is 60% below median its 10-year median of 2.01. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 18.49. The Medical Devices & Instruments industry median PB Ratio is 2.02. MaxCyte's value of 0.80 is 60.4% below this industry median. Based on the distribution chart, MaxCyte ranks #119 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's PB Ratio compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #119 out of 788 companies for PB Ratio. This places MaxCyte in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.02. MaxCyte's value of 0.80 is 60.4% below this benchmark. Historically, MaxCyte's own PB Ratio has ranged from 0.43 to 18.49 over the past decade. While the company's 10-year median is 2.01 vs. the industry median of 2.02, MaxCyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current PB Ratio of 0.80 is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current PB Ratio is 0.80, which is 60% below median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.25 — trading 51.4% below its estimated fair value. The current PB Ratio is 0.80, which is 60% below median its 10-year median of 2.01 and 60.4% below the Medical Devices & Instruments industry median of 2.02. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current PB Ratio is 0.80 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.25 is trading 51.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
PB Ratio: 0.80 (60% below median its 10-year median of 2.01)
GF Value™: $2.57 vs. price of $1.25 (51.4% below fair value)
Industry Position: 60.4% below the Medical Devices & Instruments median (#119 of 788)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
